Balance Sheet
Cash Flow Statement
Cash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in CashChange in ReceivablesChange in ReceivablesDepreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and DepletionDepreciation and DepletionExchange Rate EffectExchange Rate EffectFree Cash FlowFree Cash FlowNet Cash FlowNet Cash FlowNet IncomeOther Working Capital ChangesOther Working Capital ChangesShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Alterity Therapeutics (ATHE) Net Cash Flow (2016 - 2020)

Alterity Therapeutics has reported Net Cash Flow over the past 3 years, most recently at -$5.2 million for Q4 2018.

  • For Q4 2018, Net Cash Flow fell 455.25% year-over-year to -$5.2 million; the TTM value through Jun 2019 reached -$6.2 million, down 2.99%, while the annual FY2025 figure was $13.4 million, 703.03% up from the prior year.
  • Net Cash Flow for Q4 2018 was -$5.2 million at Alterity Therapeutics, down from -$47278.4 in the prior quarter.
  • Over five years, Net Cash Flow peaked at -$47278.4 in Q2 2018 and troughed at -$5.5 million in Q2 2016.
  • A 3-year average of -$2.8 million and a median of -$2.7 million in 2017 define the central range for Net Cash Flow.
  • On a YoY basis, Net Cash Flow climbed as much as 98.93% in 2018 and fell as far as 455.25% in 2018.
  • Year by year, Net Cash Flow stood at -$598231.8 in 2016, then tumbled by 56.04% to -$933486.7 in 2017, then tumbled by 455.25% to -$5.2 million in 2018.
  • Business Quant data shows Net Cash Flow for ATHE at -$5.2 million in Q4 2018, -$47278.4 in Q2 2018, and -$933486.7 in Q4 2017.